This application is a national stage entry under 35 U.S.C. § 371 of PCT/US98/17232, filed August 20, 1998 which is a continuation-in-part of application Serial Number 08/916,575, filed August 22, 1997, now abandoned.

IN THE CLAIMS

Cancel claims 26-32 as directed to non-elected subject matter.

Cancel claims 1-25 and rewrite as the following new claims:

33. (New) A compound having a Formula I:



I

wherein

A is a lipophilic group comprising an aliphatic bridging group,

B is a lipophilic group,

R is hydrogen, alkyl, or cycloalkyl, and

D is

 or 

wherein

R^1 is hydrogen, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl, and

R^2 and R^3 are independently hydrogen, alkyl, substituted alkyl, acyl, amidino, alkoxycarbonyl, or either R^2 or R^3 can be taken together with R^1 to form alkylene, and

R^2 and R^3 can be taken together to form alkylene which may have a hetero atom, and

M^2 is:





or



wherein

x, y and z are independently an integer of 0 to 4, and

R^5, R^6, R^7 and R^8 are independently hydrogen, halogen, alkyl, substituted alkyl,—OR^9, —R^9, —R^9R^{10}, —NHC(O)R^9, —C(O)OR^9, —COR^9, —OC(O)OR^9, —$CONR^9R^{10}$, or can be taken together with R^1 or R^2 to form alkylene which may have a hetero atom,

R^9 and R^{10} are independently hydrogen, alkyl, substituted alkyl, and

R^9 can be taken together with R^1 or R^2 to form alkylene,

R^5 and R^7 or R^6 and R^8 can be taken together to form alkylene which may have a hetero atom, or

R^5 and R^6 or R^7 and R^8 can be taken together with the carbon atom to which

R^5 and R^6, or R^7 and R^8 are bonded, respectively, to form carbonyl, thiocarbonyl or imino, and

E is oxygen atom or sulfur atom,

and pharmaceutically acceptable salts and individual isomers thereof.

34. (New) A compound or pharmaceutically acceptable salts or individual isomers thereof according to claim 33 wherein A is:

$$A^1 - M^1 -$$

wherein

A^1 is an aliphatic or aromatic ring which may have at least one hetero atom, and

M^1 is substituted or unsubstituted alkylene.

35. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 34 wherein A^1 is:



wherein

A^2 is single or fused ring, each ring constituting A^2 is an aliphatic or aromatic ring which may have at least one hetero atom, each ring constituting A^2 may be substituted by at least one group selected from halogen, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, perfluoroalkyl, perfluoroalkoxy, cyano, nitro, substituted sulfonyl, substituted sulfenyl, substituted sulfinyl, mercapto, substituted carbonyl, amino, substituted amino, aryl, and substituted aryl, and

M^1 is alkylene which may be substituted by halogen, hydroxy, $(C_1—C_5)$alkyl, and/or $(C_1—C_5)$alkoxy.

36. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 34 wherein A^1 is:



wherein

A^3 is a 5, 6, or 7 membered aromatic ring which include at least one hetero atom, and may be substituted by a group selected from halogen, hydroxy, $(C_1—C_5)$alkyl, $(C_1—C_5)$alkoxy, $(C_1—C_5)$perfluoroalkyl, $(C_1—C_5)$perfluoroalkoxy, nitro, cyano, substituted sulfonyl, substituted sulfenyl, substituted sulfinyl, mercapto, amino, substituted amino, substituted carbonyl, phenyl and/or substituted phenyl, or

A^3 can be fused with at least 5 to 8 membered aliphatic or aromatic ring which may include at least one hetero atom, and

l is 0, 1, or 2, and

X is $—CH_2—$, —O—, —S(O)r—, —C(O)—, —C(S)—, —CH=CH—, —CH(OH)—, or $—NR^4—$, and

R^4 is hydrogen, $(C_1—C_5)$alkyl, $(C_3—C_8)$cycloalkyl, acyl, or alkoxycarbonyl, and m is 0, 1, or 2, and

Y is —C(O)—, —C(S)—, or $(C_1—C_5)$alkylene which may be substituted by $(C_1—C_5)$alkyl,

p is 0, 1, or 2, and

r is 0,1, or 2, and

Z is substituted or unsubstituted(C_1—C_5)alkylene,—NR^4—, or



wherein

A^4 is a 5 or 6 membered aromatic ring which may be comprised of at least one hetero atom, and

A^4 may be substituted by a group selected from halogen, hydroxy, (C_1—C_5) alkyl, (C_1—C_5)alkoxy, (C_1—C_5)perfluoroalkyl, (C_1—C_5)perfluoroalkoxy, nitro, cyano, amino, substituted amino, phenyl and/or substituted phenyl, or



wherein

G_1 and G_2 are independently carbon or nitrogen, and

one of ⚌ may represent double bond when either G_1 and G_2 or G_2 and G_3 are carbon, and

G_3, G_4, and G_5 are independently —O—, —S(O)r—, —C(O)—, —C(S)—, —CH=CH—, —CH(OH)—, —NR^4—, or (C_1—C_5)alkylene ,

r is 0, 1, or 2, and

n is 0 or 1.

37. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 36 wherein A^1 is selected from:

10,11-Dihydrodibenzo[b,f][1,4]oxazepin-11-one,

3,4-Dihydro-2h-quinoline,

2-Oxo-3,4,5,6 - tetrahydro-2h-benzo[b]azocine,

2,3-Dioxo-2,3-dihydro-indole,

2-Oxo-3,4-dihydro-2h-quinoline,

3 - Oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazine,

4 - Methyl - 2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepine,

2,3 - Dihydro-1h-pyrrolo[2,1-c] [1,4]benzodiazepin-5,11(10h,11ah) - dione,

3-Oxo-2,3 - dihydro-benzo[l,4]thiazine,

6 - Oxo-11,12-dihydro - 6h - dibenzo[b,f]azocine,

2-Oxo-2,3,4,5-tetrahydrobenzo[b]azepine,

1,1,4-Trioxo-2,3- dihydro-benzo[1,5]thiazepine,

4-Oxo-2,3-dihydro-1,5-benzothiazepine,

5,11-Dihydro-dibenzo[b,e]azepine,

5H - Dibenzo[b,e]azepin - 6,11-dione,

5H-Dibenzo[b,f]azocin-6-one,

10H-Dibenzo[b,f][1,4]thiazepin-11 - one,

5-Oxo-5,10h-dibenzo[b,f][1,4]thiazepin-11 - one,

5,5 - Dioxo-5,10h-dibenzo-[b,f][1,4]thiazepin-11-one,

4-Oxo-2,3-dihydro-[1,5]benzoxazepine,

6,12-Dioxo-6,6a,7,8,9,10-exahydro-12h-benzo[e]-pyrido[1,2-a][1,4]diazepine,

2-Oxo-2h-cyclohepta-4,6,8-trieno[b]pyrrole, and

phenothiazine, each of which may be substituted.

38. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 33 wherein:

B is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, or aryl, arylalkyl or arylalkoxyalkyl which may be substituted on their aromatic ring.

39. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 33 wherein:

B is phenylalkyl, naphthylalkyl, 5,6,7,8-tetrahydro-naphthylalkyl, indolylalkyl, quinolylalkyl, or phenylalkoxyalkyl, which may be substituted by a group selected from halogen, hydroxy, (C_1—C_5)alkyl, (C_1—C_5)alkoxy, nitro, cyano, amino, substituted amino, phenyl, or substituted phenyl.

40. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 33 wherein:

R^1 is hydrogen, (C_1—C_5)alkyl, (C_3—C_8)cycloalkyl, (C_1—C_5)hydroxyalkyl, or (C_1—C_5)aminoalkyl, and

R^2 and R^3 are independently hydrogen, (C_1—C_5)alkyl, substituted (C_1—C_5)alkyl, (C_1—C_6)acyl, or (C_1—C_6)alkoxycarbonyl, and

R^1 and R^2 or R^2 and R^3 are can be taken together to form alkylene,

R^5, R^6, R^7, and R^8 are independently hydrogen, halogen, (C_1—C_5)alkyl, substituted

$(C_1—C_5)$alkyl, $—OR^9$, $—SR^9$, $—NR^9R^{10}$, $—OC(O)OR^9$, $—NHC(O)R^9$, $—C(O)OR^9$, and

R^5 can be taken together with R^1 or R^2 to form alkylene,

R^9 and R^{10} are independently hydrogen, $(C_1—C_5)$alkyl, and

R^9 can be taken together with R^1 or R^2 to form alkylene.

41. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 40 wherein D is selected from:







or

42. (New) A compound selected from:

N-(2-Aminoethyl)-3-phenyl-2(R)-[2-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;

3-(3-Acetylamino-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-N-[1(R)-(2-amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;

N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H- dibenzo[b,f]azocin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro[1,5] benzothiazepin-5-yl)propionamide;

N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro- [1,5] benzothiazepin-5-yl)propionamide;

N-(4-Aminobutyl)-3-(naphthalen-2-yl)-2(R)-[2-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H- dibenzo [b,f][1,4]oxazepin-10-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H-(11aS)-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-yl)propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[3,2-b][1,4]oxazin-4-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;

N-(2-Amino-2-methylpropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)-propionylamino]propionamide;

C12 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(3-oxo-2,3-dihydro-benzo[1,4]thiazin-4-yl)butyramide;

N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(1(R)-[(3-Aminopropyl)-methylcarbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)-propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-

dihydro-[1,6]benzothiazepin-5-yl)butyramide;

N-[1(R)-(2-Amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(1(R)-[Bis-(3-aminopropyl)carbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-phenothiazin-10-yl-propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)2(R)-[3-(2-oxo-2,3,4,5-tetrahydro-benzo [b]azepin-1-yl)propionylamino]propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo [b]azocin-1-yl)propionylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

N-[1(R)-(2-aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(1H-indol-3-yl)-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H- ibenzo[b,f][1,4]oxazepin-10-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,4-dioxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo -2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-fluoro-4-oxo-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H,(11aS)-pyrrolo[2,1-c][1,4]diazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(phenothiazin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)butyramide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalene-2-yl)ethyl]-3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalene-2-yl)-2(R)-[3-(4-oxo-7-trifluoromethyl-

2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

C2

N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]-azepin-5-yl)propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo-[b,e]-azepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]thiazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H- dibenzo[b,f][1,4]-thiazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,11-dioxo-5,11-dihydrodibenzo-[b,f][1,4]thiazepin-10-yl)pentanamide;

C2

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,5,11-trioxo-5,11-dihydro-dibenzo[b,f][1,4]thiazepin-10-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-chloro-5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl) propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,12-dioxo-6,6a,7,8,9,10-hexahydro-12H-benzo[e]pyrido[1,2-a][1,4]diazepine-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(9-fluoro-2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]-thiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-amino-2(S)-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl) propionamide;

N-[1(R)-(3-amino-2(R)-hydroxy-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)buthanamide;

C2

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl) propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(1,1,4-trioxo-benzo-[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxycarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-3,4-dihydro[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxycarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-cyano-5-isopropyl-2-oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrol-1-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxycarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-10-yl)propionamide; and

N-[1(R)-[2-Hydroxy-3-(2(R)-hydroxypropylamino)propylcarbamoyl]-2-naphthalen-2-yl-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide.

43. (New) A composition which comprises an inert carrier and a compound according to claim 33.

44. (New) A composition which comprises an inert carrier, a compound according to claim 33 and a growth hormone secretagogues selected from KP-102(GHRP-2),GHRP-6, Hexarelin, GHRP-1, L-692,429, L-692,585, MK-0677,G-7220, or growth hormone releasing factor (GRF), IGF-1, IGF-2, or B-HT920 or said growth hormone.

45. (New) A method for increasing levels of endogenous growth hormones in a human or an animal which comprises administering to such human or animal an effective amount of a compound according to claim 33.

46. (New) A method for treating diseases or conditions which may be treated by growth hormone which comprises administering to a human or an animal of such treatment an amount of a compound according to claim 33 which is effective in promoting release of said growth hormone.

47. (New) A method of claim 46 wherein the disease or condition is selected from the group consisting of osteoporosis; catabolic illness; immune deficiency, hip fracture; musculoskeletal impairment in the elderly; growth hormone deficiency in adults or in children; obesity; cachexia and protein loss due to chronic illness and treatment of patients recovering from major surgery, wounds and burns.

48. (New) A method for increasing the level of growth hormone in a human or an animal which comprises administering to a human or animal a compound according to claim 33 in combination with an additional growth hormone secretagogue selected from KP-102(GHRP-2), GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor(GRF), IGF-1, IGF-2, B-HT920 or said growth hormone.

49. (New) A method for the treatment of osteoporosis which comprises administering to a patient with osteoporosis a combination of a bisphosphonate compound and a compound according to claim 33.

50. (New) A method for the treatment of bone fractures, wounds or burns which comprises administering to a patient with bone fractures, wounds or burns a combination of a growth factor and a compound according to claim 33.

51. (New) The method of claim 50 wherein the growth factor is fibroblast growth factor (FGF) or platelet-derived growth factor (PDGF).

52. (New) A method to increase the rate and extent of growth of animals, to increase the milk or wool production of animals the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 33.

53. (New) A process for the preparation of a compound of claim 33 which comprises reacting a compound having a formula:

$$A-CO-R^{11}$$

wherein R^{11} is a leaving group and A is as defined in claim 33 with a compound having a formula:



wherein R, B and D are as defined in claim 33.

54. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 33 wherein D is selected from:



and

55. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 33 wherein R is hydrogen.

56. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 34 wherein A^1 is selected from:



587128

57. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 55 wherein M^1 is selected from:



58. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 55 wherein B is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, or aryl, arylalkyl or arylalkoxyalkyl which may be substituted on their aromatic ring.

59. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 57 wherein D is selected from:







and

60. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 57 wherein D is selected from:


NH2
NH2
NH2
H3C
CH3
NH2
OH
NH2
NHMe
OH
OH
Me
NH2
N
NH2
and
CH3
N
NH2